Skip to main content
Jacobio Pharmaceuticals Group Co., Ltd. logo

Jacobio Pharmaceuticals Group Co., Ltd. — Investor Relations & Filings

Ticker · 1167 HKEX Manufacturing
Open in API
Filings indexed 298 across all filing types
Latest filing 2026-05-04 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1167

About Jacobio Pharmaceuticals Group Co., Ltd.

http://www.jacobiopharma.com

Jacobio Pharmaceuticals Group Co., Ltd. is a biopharmaceutical company specializing in the in-house discovery and development of innovative oncology therapies. The company is committed to providing breakthrough treatment solutions for patients by focusing its research and development pipeline on six major tumor signaling pathways: KRAS, Tumor Immunity, Tumor Metabolism, P53, RB, and MYC. Jacobio utilizes advanced drug discovery platforms, including induced allosteric mechanisms, to develop novel and improved medicines. The company primarily focuses on developing new drugs at the clinical stage, with the strategic goal of positioning its core projects among the top three globally in their respective therapeutic areas.

Recent filings

Filing Released Lang Actions
NEXT DAY DISCLOSURE RETURN
Regulatory Filings
2026-05-04 English
NEXT DAY DISCLOSURE RETURN
Regulatory Filings
2026-04-30 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is a Next Day Disclosure Return (Form FF305) under HKEX rules detailing the company’s share repurchase activity (changes in issued shares, treasury shares, repurchase dates, prices, and volumes). This is a report of the company buying back its own shares, fitting the definition of a Transaction in Own Shares (POS).
2026-04-29 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is a Hong Kong Exchange Form FF305 “Next Day Disclosure Return” detailing changes in issued shares and treasury shares, including a share repurchase of 65,400 ordinary shares on 28 April 2026, prices paid, and closing balances. This is a report of the company buying back its own shares. It is not an earnings announcement, management commentary, or general report publication notice; it specifically falls under share repurchase and treasury share transactions. Therefore, it best fits the “Transaction in Own Shares” category (POS).
2026-04-28 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is a Next Day Disclosure Return under HKEx Main Board and GEM Rules, detailing changes in issued shares and treasury shares, specifically the repurchase of 66,000 shares and on-market sale of treasury shares. This is a mandated disclosure of the company’s own share transactions (repurchases held as treasury shares). This fits the “Transaction in Own Shares” category (Code: POS).
2026-04-27 English
FORM OF PROXY FOR THE 2026 ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a Form of Proxy for the 2026 Annual General Meeting, used to appoint proxies and vote on AGM resolutions. It is clearly a solicitation and information statement sent to shareholders to request votes at the AGM rather than the AGM minutes or full report. This matches the definition of a Proxy Solicitation & Information Statement (PSI).
2026-04-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.